ArQule to Report Third Quarter 2013 Financial Results on November 7, 2013 Business Wire WOBURN, Mass. -- October 31, 2013 ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the third quarter of 2013 on Thursday, November 7, 2013 at 7:00 a.m. Eastern Time. The Company will hold a conference call at 9:00 a.m. Eastern Time that day to discuss these results. Conference Call and Webcast Date: Thursday, November 7, 2013 Time: 9:00 a.m., Eastern Time Conference Call Numbers Domestic (toll free): (877) 868-1831 International: (914) 495-8595 Webcast: www.arqule.com A replay of the conference call will be available beginning two hours after the completion of the call through November 9, 2013 and can be accessed by dialing toll-free 855-859-2056 or 800-585-8367 and from outside the U.S. 404-537-3406. The confirmation code for replayed calls is 86068331. About ArQule ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase, and ARQ 087, designed to inhibit fibroblast growth factor receptor (FGFR). ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase. Contact: ArQule, Inc. William B. Boni, 781-994-0300 VP, Investor Relations/ Corp. Communications www.ArQule.com
ArQule to Report Third Quarter 2013 Financial Results on November 7, 2013
Press spacebar to pause and continue. Press esc to stop.